ArticleNeurology. Clinical practice2025
Community Disadvantage Is Associated With More Severe Motor Symptoms in Parkinson Disease.
Article in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Socioeconomic Status on the Risk of Disability Registration and Cognitive Decline in Patients With Parkinson's Disease: A Nationwide Cohort Study.Journal of movement disorders · 2026Article
- Income, employment, and clinical outcomes in Parkinson's disease.Clinical parkinsonism & related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The relationship between socioeconomic factors and Parkinson disease (PD) is unclear. Previous literature suggests a potential disconnect between the effect of socioeconomic status (SES) on PD risk and severity. A recent study found that people with PD in the United States were more likely to come from well-resourced communities. Multiple possible explanations were proposed, including that lower SES could be protective against PD risk. Other studies have found worsened PD symptoms and outcomes associated with lower individual SES. If environmental factors associated with lower SES influence PD biology in a way that worsens symptoms, those processes should also increase PD risk. We set out to determine whether community disadvantage, rather than individual SES, is associated with motor or cognitive symptom severity in PD and atypical parkinsonisms. Methods: Community disadvantage was defined using the Material Community Deprivation Index, a compound score of multiple poverty markers. In our Cincinnati Cohort Biomarkers Program, a cohort that includes PD and atypical parkinsonisms, we tested for associations between community disadvantage and motor symptom severity (Movement Disorders Society Unified PD Rating Scale part III; MDS-UPDRS III), motor disability (Hoehn and Yahr stage [HY]), and cognition (Montreal Cognitive Assessment [MoCA]). We considered age, sex, disease duration, levodopa equivalent daily dose, education years, and race as covariates in multiple regression analyses. Results: A total of 565 people with PD or atypical parkinsonisms were included (458 idiopathic PD and 107 atypical parkinsonisms). Their mean age was 69 years, and 65% were men. The mean disease duration was 7 years, and the mean MDS-UPDRS III score was 30. The majority (75%) were HY stage 2, and the mean cognitive screening score was nondemented (MoCA 25/30). Worse community disadvantage was significantly associated with worse MDS-UPDRS III score (β 1.58, Discussion: Community disadvantage was associated with worse motor symptom severity and motor disability in PD, suggesting that there are modifiable social and environmental factors that can affect parkinsonian symptom severity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.